Victor Johan Bernard Huiskes

Victor Johan Bernard Huiskes

Auto-generated profile, based on publicly available information

Victor Johan Bernard Huiskes

Department of Pharmacy, Radboudumc, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2017 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
VHVictor Johan Bernard Huiskes
Victor Johan Bernard Huiskes
DBDavid Marinus Burger
David Marinus Burger
CECornelia Van den Ende
Cornelia Van den Ende
BBBart Van den Bemt
Bart Van den Bemt
Medication review is often recommended to optimize medication use. In clinical practice it is mostly operationalized as an intervention without co-interventions during a short term intervention period. However, most systematic reviews also included co-interventions and prolonged medication optimization interventions. Furthermore, most systematic reviews focused on specific patient groups (e.g. polypharmacy, elderly, hospitalized) and/or on specific outcome measures (e.g. hospital admissions and mortality). Therefore, the objective of this study is to assess the effectiveness of medication review as an isolated short-term intervention, irrespective of the patient population and the outcome measures used. A literature search was performed in MEDLINE, EMBASE and Web of Science from their inception through September 2015. Randomized controlled trials (RCTs) with medication review as isolated short term intervention (<3 months) were included. There were no restrictions with regard to patient characteristics and outcome measures. One reviewer extracted and a second checked data. The risk of bias of studies was evaluated independently by two reviewers. A best evidence synthesis was conducted for every outcome measure used in more than one trial. In case of binary variables a meta-analysis was performed in addition to the best evidence synthesis, to quantify the effect. Thirty-one RCTs were included in this systematic review (55% low risk of bias). A best evidence synthesis was conducted for 22 outcome measures. No effect of medication review was found on clinical outcomes (mortality, hospital admissions/healthcare use, the number of patients falling, physical and cognitive functioning), except a decrease in the number of falls per patient. However, in a sensitivity analysis using a more stringent threshold for risk of bias, the conclusion for the effect on the number of falls changed to inconclusive. Furthermore no effect was found on quality of life and evidence was inconclusive about the effect on economical outcome measures. However, an effect was found on most drug-related problems: medication review resulted in a decrease in the number of drug-related problems, more changes in medication, more drugs with dosage decrease and a greater decrease or smaller increase of the number of drugs. An isolated medication review during a short term intervention period has an effect on most drug-related outcomes, minimal effect on clinical outcomes and no effect on quality of life. No conclusion can be drawn about the effect on economical outcome measures. Therefore, it should be considered to stop performing cross-sectional medication reviews as standard care.

2 April 2018 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
LTLieke Tweehuysen
Lieke Tweehuysen
VHVictor J. B. Huiskes
Victor J. B. Huiskes
BBBart J. F van Den Bemt
Bart J. F van Den Bemt
JVJohanna E. Vriezekolk
Johanna E. Vriezekolk
STSteven Teerenstra
Steven Teerenstra
ABAlfons A. Den Broeder
Alfons A. Den Broeder
Objective: To evaluate the effects of non‐mandatory transitioning from the originator biologic drug etanercept (ETN) to its biosimilar, SB4, on drug survival and effectiveness in a controlled cohort study of patients with an inflammatory rheumatic disease.Methods: In 2016, 642 patients were asked to transition their treatment from originator ETN to biosimilar SB4 by a structured communication strategy with opt‐out option. Patients who consented to switch to SB4 were considered eligible for inclusion in the transition cohort, while patients being treated with originator ETN in 2014 were recruited as the historical cohort. Drug survival was compared between the 2 cohorts using Cox regression analyses, which were adjusted for age, sex, diagnosis, ETN treatment duration, ETN dose interval, conventional synthetic disease‐modifying antirheumatic drug usage, and C‐reactive protein (CRP) level, with a robust variance estimator applied to account for repeated subjects (i.e., patients who were included in both the transition cohort and the historical cohort). Adjusted differences in the 6‐month change in CRP level, Disease Activity Score in 28 joints using CRP level (DAS28‐CRP), and Bath Ankylosing Spondylitis Disease Activity Index were also assessed.Results: Of the 642 ETN‐treated patients, 635 (99%) agreed to transition from originator ETN to biosimilar SB4, of whom 625 patients (433 with rheumatoid arthritis, 128 with psoriatic arthritis, and 64 with ankylosing spondylitis) were included in the transition cohort, and 600 ETN‐treated patients from 2014 were included in the historical cohort. The crude treatment persistence rate for biosimilar SB4 over 6 months was 90% (95% confidence interval [95% CI] 88–93%), compared to a 6‐month treatment persistence rate of 92% (95% CI 90–94%) for originator ETN. Patients in the transition cohort, compared to the historical cohort, had a statistically significantly higher relative risk of treatment discontinuation (adjusted hazard ratio 1.57, 95% CI 1.05–2.36) and showed smaller decreases in the CRP level (adjusted difference 1.8, 95% CI 0.3–3.2) and DAS28‐CRP (adjusted difference 0.15, 95% CI 0.05–0.25) over 6 months.Conclusion: Non‐mandatory transitioning from originator ETN to biosimilar SB4 using a specifically designed communication strategy resulted in a slightly lower 6‐month treatment persistence rate and smaller decreases in disease activity in the transition cohort compared to the historical cohort, but these differences were not considered clinically relevant.

15 May 2015 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
CWCarli Michèle Wilmer
Carli Michèle Wilmer
VHVictor Johan Bernard Huiskes
Victor Johan Bernard Huiskes
SNStephanie Natsch
Stephanie Natsch
ARAlexander Johannes Maria Rennings
Alexander Johannes Maria Rennings
BBBartholomeus Johannnes Frederikus van Den Bemt
Bartholomeus Johannnes Frederikus van Den Bemt
JBJacqueline Maria Bos
Jacqueline Maria Bos
Objectives This study aims to summarise existing evidence on risk factors for drug-related problems (DRPs) in hospitals as well as ambulatory care or nursing homes and adds additional empirical evidence on risk factors for DRPs in non-elective hospitalised patients. Methods A comprehensive literature review was performed to compose an overview of demographic, clinical and pharmacological risk factors associated with DRPs in different settings (ambulatory care, nursing homes and hospitals). A cross-sectional study on rehabilitation, cardiology and pulmonology wards of three hospitals in Nijmegen, the Netherlands, was performed to assess possible risk factors for DRPs in a clinical setting. Results The comprehensive review identified 21 papers discussing risk factors for drug-related hospital admissions, use of potential inappropriate drugs, adverse drug reactions and other types of DRPs. The majority of these studies had been carried out in ambulatory care (11 papers; 52%). Polypharmacy, comorbidity and the use of specific drugs (antithrombotics, antidiabetics) were most often positively associated with the occurrence of DRPs. Our cross-sectional study demonstrated that admission to the rehabilitation ward, admission at the intensive care unit and comorbidity were associated with the occurrence of potential DRPs in a clinical setting. Conclusions Although risk factors associated with DRPs differ greatly among published papers, comorbidity, polypharmacy and the use of specific drugs (antithrombotics, antidiabetics) were frequently associated with DRPs. Although several guidelines advise to use prespecified risk factors (like age, polypharmacy and renal impairment), one should be aware that most of these risk factors are insufficiently grounded on empirical evidence.

30 September 2019 in Rheumatology
Verified
Journal Article
Closed access
LKLeanne J Kosse
Leanne J Kosse
NJNaomi T Jessurun
Naomi T Jessurun
RHRenske C F Hebing
Renske C F Hebing
VHVictor J B Huiskes
Victor J B Huiskes
KSKarin M Spijkers
Karin M Spijkers
MNMike T Nurmohamed
Mike T Nurmohamed
Objectives: Assessment of the quality of patient-reported medical information in the Dutch Biologic Monitor and evaluation of the representativeness of the sampled participants. Methods: Consecutive adult patients using a biologic DMARD (bDMARD) for an immune-mediated inflammatory disease were included in eight Dutch centres. For this substudy, data of 550 patients with inflammatory rheumatic diseases were used. Patient-reported bDMARD prescription, indication and combination therapy were verified for patients that permitted access to their electronic health record using percentage agreement and/or Cohen’s kappa (n = 483). Conservative post hoc sensitivity analysis was performed to account for missing data. Population representativeness was tested for the entire substudy population by comparing age, gender and prescribed bDMARD to the centres’ reference populations using Mann–Whitney U-test, χ2 goodness-of-fit or Fisher’s exact test with Monte Carlo simulation (n = 550). Results: The correct bDMARD was reported by 95.8% of the participants. Agreement between patients and electronic health record was almost perfect for indications (κ = 0.832) and substantial for combination therapies (κ = 0.725). Agreement on combination therapies remained substantial after post hoc sensitivity analysis (κ = 0.640). Gender distribution (P > 0.05) and bDMARD use (P > 0.05) were similar to the reference populations. Median age was different (58.0 vs 56.0 years, P = 0.04), but considered clinically irrelevant. Conclusion: The Dutch Biologic Monitor seems to be a valid tool to obtain patient-reported medical information. Reported medical information generally corresponded to the electronic health records and the participants represented their reference populations regarding age, gender and prescribed bDMARD.

29 October 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
VHVictor Johan Bernard Huiskes
Victor Johan Bernard Huiskes
CECornelia Helena Maria van Den Ende
Cornelia Helena Maria van Den Ende
MKMartine Kruijtbosch
Martine Kruijtbosch
HEHendrik Tinus Ensing
Hendrik Tinus Ensing
MMMarieke Meijs
Marieke Meijs
BBBartholomeus Johannes Fredericus van Den Bemt
Bartholomeus Johannes Fredericus van Den Bemt

1 February 2009 in Prostaglandins, Leukotrienes and Essential Fatty Acids
Verified
Journal Article
Closed access
VHVictor J.B. Huiskes
Victor J.B. Huiskes
RKRemko S. Kuipers
Remko S. Kuipers
FVFrancien V. Velzing-Aarts
Francien V. Velzing-Aarts
DDD.A. Janneke Dijck-Brouwer
D.A. Janneke Dijck-Brouwer
JMJan van der Meulen
Jan van der Meulen
FMFrits A.J. Muskiet
Frits A.J. Muskiet